Longevity Health Holdings Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $297.8K
- Price
- $0.1203
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.61%
- Volume
- 435
About
Longevity Health Holdings Inc. specializes in creating plasma-based bioactive materials (PBMs) aimed at fostering tissue regeneration and repair in response to injury, illness, and the natural aging process. The company's primary investigational product is CT-101, which acts as a powerful accelerant for bone healing in diverse applications such as tibia fracture recovery, foot/ankle and spinal fusions, serving as a dental bone graft substitute, and filling bone voids. Additionally, CT-101 functions as a tissue healing accelerant, offering potential for treating androgenetic alopecia and persistent chronic wounds. Established in 2008, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Quick stats
Shares outstanding2.5M
Computed float1.6M
Float / shares65.0%
Cash runway (months)2
Key info
SectorConsumer Defensive
IndustryHousehold & Personal Products
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001842939
Websitehttps://healthxage.com
AI Summary
AI-generated1/7
standardbearishdebt offering
Longevity Health Holdings Enters into Securities Purchase Agreement for Up to $625,000 in Gross Proceeds
Longevity Health Holdings entered a securities purchase agreement with institutional investor Puritan Partners for up to $625,000 in aggregate gross proceeds through a series of 10% senior secured convertible notes, each issued with a 10% original issue discount.
At the August 31, 2026 initial closing the company drew $375,000 gross, issuing a note with $416,666.67 original principal, 10% annual interest, a February 29, 2028 maturity, and conversion into common stock at $0.50 per share, subject to adjustment. The note is secured by substantially all of the assets of the company and its subsidiaries.
Two additional $125,000 tranches remain available on substantially the same terms: the second is contingent on effectiveness of a resale registration statement covering the underlying shares, and the third is at Puritan's sole discretion.
The heavy discount, blanket lien, and small size signal constrained access to capital, with dilution risk if the notes convert into common stock at $0.50.
Red flags
- notes secured by substantially all assets of the company and its subsidiaries (blanket lien)
- 10% original issue discount plus 10% coupon implies a high effective cost of capital
- conversion at $0.50 per share subject to adjustment creates dilution risk
- future tranches contingent on registration effectiveness or investor sole discretion
- very small raise size (up to $625K) suggests limited alternative financing options